ECSP045200A - ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS - Google Patents

ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS

Info

Publication number
ECSP045200A
ECSP045200A EC2004005200A ECSP045200A ECSP045200A EC SP045200 A ECSP045200 A EC SP045200A EC 2004005200 A EC2004005200 A EC 2004005200A EC SP045200 A ECSP045200 A EC SP045200A EC SP045200 A ECSP045200 A EC SP045200A
Authority
EC
Ecuador
Prior art keywords
alcoxipropanoicos
imidazolil
acids
alkyl
hydrogen
Prior art date
Application number
EC2004005200A
Other languages
Spanish (es)
Inventor
Charlotte Moira Norfor Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP045200A publication Critical patent/ECSP045200A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de acuerdo con la fórmula (I) en la que n es 0-3, R1 es alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 o alquinilo C2-6, heterociclo, heterociclo aromático, arilo o hidrógeno y cada uno de R2, R3, R4, R5, R6, R7, R8 y R9 se selecciona independientemente entre hidrógeno y alquilo C1-6 opcionalmente sustituido, o R5 y R8 son una cadena alquileno, son novedosos. Estos compuestos son útiles en el tratamiento de afecciones trombóticas y otras patologías asociadas con la deposición de fibrina.The compounds according to formula (I) in which n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, heterocycle, aromatic heterocycle, aryl or hydrogen and each of R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, they are novel. These compounds are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.

EC2004005200A 2002-01-22 2004-07-22 ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS ECSP045200A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
ECSP045200A true ECSP045200A (en) 2004-08-27

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005200A ECSP045200A (en) 2002-01-22 2004-07-22 ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
US20060234986A1 (en) * 2005-04-18 2006-10-19 Schering Aktiengesellschaft Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI
WO2010050525A1 (en) 2008-10-29 2010-05-06 大正製薬株式会社 Compound having tafia inhibitory activity
TW201033184A (en) 2008-12-05 2010-09-16 Mochida Pharm Co Ltd Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
JP5778133B2 (en) * 2010-03-18 2015-09-16 第一三共株式会社 Cyclopropanecarboxylic acid derivative
CN102803226B (en) 2010-03-18 2016-05-04 第一三共株式会社 The imdazole derivatives that cycloalkyl replaces
US9834527B2 (en) 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
JPWO2017170460A1 (en) 2016-03-29 2019-02-07 第一三共株式会社 Inflammatory bowel disease treatment
EP3682881A4 (en) 2017-09-14 2021-08-11 Daiichi Sankyo Company, Limited Compound having cyclic structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
PT1311488E (en) * 2000-08-17 2009-12-30 Pfizer Ltd Substituted imidazoles as tafia inhibitors

Also Published As

Publication number Publication date
EP1467731A1 (en) 2004-10-20
OA12756A (en) 2006-07-03
IL162677A0 (en) 2005-11-20
KR20040077775A (en) 2004-09-06
CA2472238A1 (en) 2003-07-31
CN1620291A (en) 2005-05-25
EA200400716A1 (en) 2004-12-30
JP2005520811A (en) 2005-07-14
TNSN04121A1 (en) 2006-06-01
HRP20040659A2 (en) 2004-10-31
AR038197A1 (en) 2005-01-05
TW200302094A (en) 2003-08-01
UY27615A1 (en) 2003-08-29
PL371487A1 (en) 2005-06-13
PA8563501A1 (en) 2004-08-31
MXPA04006573A (en) 2004-10-04
AP2004003084A0 (en) 2004-09-30
BR0307016A (en) 2004-11-03
MA27167A1 (en) 2005-01-03
WO2003061652A1 (en) 2003-07-31
WO2003061652A8 (en) 2004-09-10
PE20030929A1 (en) 2003-11-05
IS7310A (en) 2004-06-14
NO20043457L (en) 2004-08-19

Similar Documents

Publication Publication Date Title
UY27522A1 (en) PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
NO20005237D0 (en) Heterocyclic substituted amides used as calpain inhibitors
NO20052469L (en) Inhibitors of II-beta-hydroxysteroid dehydrogenase type 1 and type 2.
PE20050999A1 (en) NOVEL KETOAMIDES WITH CYCLIC P4 AS INHIBITORS OF NS3 SERINE PROTEASE FROM HEPATITIS C VIRUS
PE20040688A1 (en) KINASE INHIBITORS
AR025225A1 (en) PHYSYLOXAZOLIDINONES HETEROCICLIC BICYCLIC REPLACED ANTIBACTERIAL AND PHARMACEUTICAL COMPOSITIONS
PE20071136A1 (en) DERIVATIVES OF ANILINE SUBSTITUTED AS ANTAGONISTS OF HISTAMINE H3
ATE404538T1 (en) TETRAHYDROPYRANYLCYCLOPENTYLTETRAHYDROISOCHINO-LINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
PE20030471A1 (en) IMIDAZOPIRIDIN COMPOUND AS 5-HT4 RECEIVER MODULATORS
PE20050226A1 (en) ARIL-HETEROAROMATIC PRODUCTS AND COMPOSITIONS CONTAINING THEM
CO5580762A2 (en) LIPOXINE A4 ANALOGS
CO6150147A2 (en) DERIVED FROM 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS
ECSP045200A (en) ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS
ECSP088484A (en) SPIROCYCLIC QUINAZOLINE DERIVATIVES AS PDE7 INHIBITORS
AR042362A1 (en) DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA200701866A1 (en) STABILIZING COMPOSITION FOR HALOGEN-CONTAINING POLYMERS
EA200300523A1 (en) TRIPEPTIDYL PEPTIDASE INHIBITORS
PE20040528A1 (en) PEPTIDE-DEFORMYLASE INHIBITORS
BRPI0508471A (en) difluoroethoxy substituted hydroxy-6-phenylphenanthridines
PE20050231A1 (en) DERIVATIVES OF PIPERIDINIUM AND PYRROLIDINIUM AS ANTAGONISTS OF THE MUSCARINIC M3 RECEPTOR
MXPA04005940A (en) 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases.
CO5690508A2 (en) PESTICIDED MATTER COMPOSITIONS
AR054414A1 (en) ESPIRO-HYDANTOINE COMPOUNDS REPLACED WITH PIRIDILE. PHARMACEUTICAL COMPOSITIONS.
PE20030611A1 (en) LINEAR BASIC COMPOUNDS THAT HAVE ANTAGONIST ACTIVITY OF NK-2 AND ITS FORMULATIONS
PE20050120A1 (en) KITCHENS WITH A MODIFIED LACTONE RING